Can single-cell genomics lead to a new wave of drug targets? Celsius Therapeutics thinks so
Thursday, July 5, 2018 - 18:18
in Health & Medicine
The start-up, based on the work of Broad Institute scientist Aviv Regev, has raised $65 million to develop therapies for cancer and autoimmune disease